Cargando…
PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
Autores principales: | Kingsbury, D, Quartier, P, Arora, V, Kalabic, J, Kupper, H, Mozaffarian, N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045695/ http://dx.doi.org/10.1186/1546-0096-11-S2-P173 |
Ejemplares similares
-
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
por: Kingsbury, Daniel J., et al.
Publicado: (2014) -
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014) -
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020) -
PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013) -
Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial
por: Ruperto, Nicola, et al.
Publicado: (2014)